CA2942574A1 - Small molecule c-myc inhibitors - Google Patents

Small molecule c-myc inhibitors Download PDF

Info

Publication number
CA2942574A1
CA2942574A1 CA2942574A CA2942574A CA2942574A1 CA 2942574 A1 CA2942574 A1 CA 2942574A1 CA 2942574 A CA2942574 A CA 2942574A CA 2942574 A CA2942574 A CA 2942574A CA 2942574 A1 CA2942574 A1 CA 2942574A1
Authority
CA
Canada
Prior art keywords
myc
mmol
pyr
added
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2942574A
Other languages
English (en)
French (fr)
Inventor
Peter K. Vogt
Francis X. Tavares
Kim D. Janda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Sorrento Therapeutics Inc
Original Assignee
Scripps Research Institute
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, Sorrento Therapeutics Inc filed Critical Scripps Research Institute
Publication of CA2942574A1 publication Critical patent/CA2942574A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2942574A 2013-12-11 2014-12-10 Small molecule c-myc inhibitors Abandoned CA2942574A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914590P 2013-12-11 2013-12-11
US61/914,590 2013-12-11
PCT/US2014/069533 WO2015089180A1 (en) 2013-12-11 2014-12-10 Small molecule c-myc inhibitors

Publications (1)

Publication Number Publication Date
CA2942574A1 true CA2942574A1 (en) 2015-06-18

Family

ID=53371801

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942574A Abandoned CA2942574A1 (en) 2013-12-11 2014-12-10 Small molecule c-myc inhibitors

Country Status (9)

Country Link
US (1) US11066398B2 (enExample)
EP (1) EP3082812A4 (enExample)
JP (1) JP6512714B2 (enExample)
KR (1) KR20160122123A (enExample)
CN (1) CN106456616A (enExample)
AU (1) AU2014363935A1 (enExample)
CA (1) CA2942574A1 (enExample)
HK (1) HK1225630A1 (enExample)
WO (1) WO2015089180A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968884A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
RU2018132559A (ru) 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения
DK3495350T3 (da) 2016-07-29 2021-12-13 Nat Cancer Ct Forbindelse som hæmmer dannelse af c-myc/max/dna-kompleks
KR101879992B1 (ko) 2016-07-29 2018-07-19 국립암센터 c-Myc/Max/DNA 복합체 형성을 억제하는 화합물
WO2018081814A1 (en) * 2016-10-31 2018-05-03 University Of Kansas Grp94 selective inhibitors and uses thereof
EP3820847B1 (en) * 2018-07-09 2022-12-14 The Scripps Research Institute Improved compounds for myc inhibition
CN109535068B (zh) * 2018-12-26 2022-07-29 中国药科大学 吡啶取代查尔酮类化合物或其可药用的盐及其制备方法和用途
CN114644626A (zh) * 2020-12-18 2022-06-21 南京施江医药科技有限公司 一种苯环类化合物及其应用
WO2022240641A1 (en) * 2021-05-12 2022-11-17 The Scripps Research Institute High-throughput assay for identification of myc inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533666A (en) * 1983-06-22 1985-08-06 Eli Lilly And Company 6-Phenyl-2,3-bis-(4-methoxyphenyl)-pyridine derivatives having anti-inflammatory activity
EP0795545A4 (en) * 1994-11-28 1998-05-06 Taisho Pharmaceutical Co Ltd PYRIDINE DERIVATIVES
AU2002247402A1 (en) * 2001-03-23 2002-10-08 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
CN101050213A (zh) * 2007-05-14 2007-10-10 中山大学 9－脂肪氨基取代小檗碱衍生物及其制备方法与作为抗癌药物的应用

Also Published As

Publication number Publication date
WO2015089180A1 (en) 2015-06-18
AU2014363935A1 (en) 2016-06-02
HK1225630A1 (zh) 2017-09-15
JP6512714B2 (ja) 2019-05-15
KR20160122123A (ko) 2016-10-21
JP2016540015A (ja) 2016-12-22
EP3082812A1 (en) 2016-10-26
US11066398B2 (en) 2021-07-20
US20160264560A1 (en) 2016-09-15
EP3082812A4 (en) 2017-04-26
CN106456616A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
US11066398B2 (en) Small molecule c-Myc inhibitors
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
KR20220133258A (ko) 화합물 및 이의 용도
Ran et al. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation
CN107531683B (zh) Usp7抑制剂化合物及使用方法
WO2020027084A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
WO2011156632A2 (en) Compositions and methods of treatment for tumors in the nervous system
CN112920176B (zh) 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用
BR112015027440B1 (pt) Derivado de [1,2,4]triazol[4,3-a]piridina, seus usos e seu processo de preparação, e composição farmacêutica
JP6979595B2 (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
Hu et al. Discovery of highly potent and efficient CBP/p300 degraders with strong in vivo antitumor activity
Ramisetti et al. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells
CN102438612B (zh) 腈衍生物及其药学用途与组合物
CA2805658C (en) Combination therapy with mdm2 and egfr inhibitors
MX2007014206A (es) Metodos para tratar cancer resistente a los farmacos.
WO2016119017A1 (en) Anti-cancer compounds
IL280539B1 (en) Late sv40 factor (lsf) inhibitors
CN107540624B (zh) 热休克蛋白抑制剂及其制备方法和应用
CN111247137A (zh) 一种嘧啶类化合物、其制备方法及其医药用途
WO2023105008A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
CN104072484B (zh) 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
CN103254203A (zh) 五元脲环并香豆素衍生物或其可药用盐及用途
CN113493407B (zh) 一种吡啶类化合物及其制法和药物用途
Luan et al. Design, synthesis and in vitro evaluation of indole derivatives bearing amide with 1, 3, 4-thiadiazole moiety as potential anticancer agents
JP2023528927A (ja) Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210302